From human analysts to agent-led funds
AI is shifting venture capital from manual research to orchestrating autonomous, multi-agent systems, with human judgment and relationships becoming the scarce advantage. A case study—Invivo Partners’ Artificial Intelligence Analyst (AIA)—shows how RLHF-trained, retrieval-grounded agents can deliver analyst-grade work in minutes while exposing new governance and data-security needs. Biotech is the proving ground, where AI-native platforms compress discovery from years to months and reshape valuations, partnerships, and exit paths.
Points clés
- AI’s growth now exceeds Moore’s law, with emergent capabilities appearing at critical compute thresholds and large language models reaching trillions of parameters.
- Cutting-edge research shows AI can decode fMRI signals into continuous words and reconstruct imagined speech and visuals, narrowing the gap between biological and artificial intelligence.
- Invivo Partners built an Artificial Intelligence Analyst (AIA) using a three-model loop—analyst, critic, and “boss”—combining OpenAI and other models to reduce hallucinations through peer review.
- AIA was trained with RLHF on years of memos and debates and grounded via retrieval layers spanning clinical trial registries, patent databases, and PubMed.
- AIA produces minutes-fast, analyst-grade outputs across pitch triage, due diligence, market maps, KOL interviews, and more, while still lacking boardroom judgment and interpersonal nuance.
- AI is reconfiguring VC roles: entry-level analyst functions are fading as associates become AI orchestrators and multi-agent “digital teams” handle research, modeling, legal review, and monitoring.
- By 2026, integrated AI stacks at leading funds raise deal throughput by roughly 50% without headcount growth, as regulators explore audits/disclosures and standards for agent-to-agent communication.
- From 2027 to 2030, the first one-person, billion-dollar fund emerges; agents make small investments under guardrails; above-human reasoning models (e.g., GPT-6) spark governance debates; at least one VC lists an AI “Principal.”
- In biotech, AI-linked wet labs compress discovery timelines from years to months, fueling higher early valuations for AI-native platforms that must still prove better clinical outcomes.
- Compute and proprietary data access become key differentiators; model weights and training pipelines require SOC-level security; patent offices and regulators grapple with AI inventorship and rogue-agent incidents.
À retenir
Practical plan, no PhD required: get AI-literate, pilot a co-pilot for triage and diligence, and lock down your data like it’s the crown jewels (because it is). Line up compute and data partnerships early, demand real proof behind AI claims—especially in biotech—and prepare for audits before regulators send you love letters. And yes, keep honing negotiation and empathy, because no, you can’t outsource gut checks to GPT-6 (yet); treat agents as power tools, not autopilots, unless you enjoy spectacularly automated mistakes.
Sources
Quiz sur le document: 10 questions
